Takeda to regulate peginesatide drug for treating anemia in CRF patients Affymax.

Morris, chief executive officer of Affymax. Predicated on our ending up in FDA, we believe the data from our completed trials are sufficient for review of our NDA because of this indication. Our goal is to post the NDA for peginesatide for the treatment of anemia in chronic renal failure sufferers on dialysis in the next one fourth of 2011. Azmi Nabulsi, M.D., M.P.H, president of Takeda Global Research & Development Middle, Inc., U.S. Added, Anemia is a common consequence of chronic kidney disease or chronic renal failure that may occur in sufferers on dialysis.National Journal: New AARP Ad Protecting Entitlements AARP is definitely premiering another national TV ad campaign today, reminding lawmakers that cutting Social and Medicare Security dangers angering 50 million seniors. Politico Pro: House Dems Part With Obama On Wellness Cuts House Energy and Commerce Democrats want the deficit reduction super committee to shun proposals that result in higher health charges for the elderly and the indegent, and instead focus on savings which can be wrung from Medicare by rooting out misdirected payments and from pharmaceutical rebates. But it also runs counter to a slate of provisions backed by President Barack Obama, who offered his own vision for deficit reduction earlier this year. The committee Democrats are also urging the 12-member panel to keep the new health care law untouched, asking associates to give the scores of applications meant to tame wellness costs an opportunity to ripen .